☆ 4.7 Article

Discovery and development of a novel N-(3-bromophenyl)- {[(phenylcarbamoyl)amino]methyl}-N-hydroxythiophene-2-carboximidamide indoleamine 2,3-dioxygenase inhibitor using knowledge-based drug design

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Chemistry, Medicinal

Discovery of IDO1 inhibitors containing a decahydroquinoline, decahydro-1,6-naphthyridine, or octahydro-1H-pyrrolo[3,2-c]pyridine scaffold

Wensheng Yu et al.

Summary: Through the study, IDO1 inhibitors containing a decahydroquinoline, decahydro-1,6-naphthyridine, or octahydro-1H-pyrrolo[3,2-c]pyridine scaffold were identified with good cellular and human whole blood activity. Compounds 15 and 27 were highlighted as leads due to their strong IDO1 inhibition activity in both cellular and human whole blood, low unbound clearance, and reasonable mean residence time in rat cassette PK studies.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)

添加到收藏夹

Article Chemistry, Medicinal

IDO1 and TDO inhibitory evaluation of analogues of the marine pyrroloiminoquinone alkaloids: Wakayin and Tsitsikammamines

Thomas Levy et al.

Summary: Indoleamine 2,3-dioxygenase (IDO1) and tryptophane 2,3-dioxygenase (TDO) are heme-containing enzymes that catalyze the conversion of tryptophan to N-formylkynurenine, playing important roles in tumor immune evasion. Analogues of marine pyrroloquinoline alkaloids were synthesized and evaluated for their ability to inhibit these enzymes, with six compounds showing significant potency on cell lines expressing hIDO1 or hTDO.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of highly potent heme-displacing IDO1 inhibitors based on a spirofused bicyclic scaffold

Olaf Kinzel et al.

Summary: Through structural modification, a novel class of highly potent IDO1-specific inhibitors was identified, with representative compound 18 showing strong inhibitory activity in cellular and whole blood assays. Pharmacokinetic profiling in mice demonstrated improved clearance compared to the original compound, and in a mouse pharmacodynamic model, compound 18 significantly suppressed kynurenine production induced by lipopolysaccharide. Hepatocyte data suggested human clearance of compound 18 is similar to linrodostat.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)

添加到收藏夹

Article Chemistry, Medicinal

Discovery and optimization of substituted oxalamides as novel heme-displacing IDO1 inhibitors

Christoph Steeneck et al.

Summary: The development of immunomodulating small molecules in oncology has gained great attention since the advent of antibody checkpoint inhibitors as highly efficient drugs for cancer treatment. Drug candidates targeting IDO1, a key enzyme in tryptophan metabolism, are currently under clinical investigation in combination with other established anti-tumor therapeutics. Different design approaches have led to new compounds with moderate to high IDO1 potency, showing promising potential in cancer treatment.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)

添加到收藏夹

Review Oncology

What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past

Yu Yao et al.

Summary: IDO1, a heme-containing enzyme, plays a crucial role in the kynurenine pathway of tryptophan metabolism, with implications in immunity and neuronal function. Despite potential applications in cancer and neurodegenerative diseases, cautionary notes from clinical trials indicate a need for better understanding of IDO1 inhibition mechanisms.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of Imidazopyridines as Potent Inhibitors of Indoleamine 2,3-Dioxygenase 1 for Cancer Immunotherapy

Liping Zhang et al.

Summary: The focus of this research is on identifying new IDO1 inhibitors for the treatment of renal cell carcinoma and metastatic melanoma. Efforts were made to find structurally differentiated IDO1 inhibitors by pursuing a variety of heterocyclic isosteres, resulting in the discovery of highly potent imidazopyridine-containing IDO1 inhibitors.

ACS MEDICINAL CHEMISTRY LETTERS (2021)

添加到收藏夹

Article Chemistry, Medicinal

Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1

Emily C. Cherney et al.

Summary: Indoleamine 2,3-dioxygenase 1 (IDO1) is a heme-containing dioxygenase enzyme involved in cancer immune response. The discovery of BMS-986242 as a novel IDO1 inhibitor offers a promising option for the treatment of various cancers. Through identifying a structurally differentiated clinical candidate with comparable efficacy to linrodostat in preclinical studies, BMS-986242 was selected for clinical development.

ACS MEDICINAL CHEMISTRY LETTERS (2021)

添加到收藏夹

Article Chemistry, Medicinal

SAR towards indoline and 3-azaindoline classes of IDO1 inhibitors

Wensheng Yu et al.

Summary: A novel series of IDO1 inhibitors has been identified, with compounds 37 and 41 standing out as potential leads due to their good potency and activity in both in vitro and in vivo studies.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)

添加到收藏夹

Article Chemistry, Medicinal

Utilization of Metabolite Identification and Structural Data to Guide Design of Low-Dose IDO1 Inhibitors

Brett Hopkins et al.

Summary: This study discusses the discovery of potent IDO1 inhibitors with low predicted human dose, achieved by strategically incorporating cyclopropane rings into the tetrahydronaphthyridine series. The development of enabling synthetic chemistry led to inhibitors with improved pharmacokinetics and human whole blood potency, with a predicted human oral dose as low as 9 mg once daily.

ACS MEDICINAL CHEMISTRY LETTERS (2021)

添加到收藏夹

Article Chemistry, Medicinal

Conformational-Analysis-Guided Discovery of 2,3-Disubstituted Pyridine IDO1 Inhibitors

Emily C. Cherney et al.

Summary: IDO1 inhibitors have shown promise as immunotherapies for treating various cancers, and recent research has identified novel heme-displacing IDO1 inhibitors, including clinical molecules like linrodostat and BMS-986242. Through efforts to swap and optimize the quinoline component, a potent and selective IDO1 inhibitor with significant pharmacodynamic activity was discovered, showing potential for further development in cancer treatment.

ACS MEDICINAL CHEMISTRY LETTERS (2021)

添加到收藏夹

Article Oncology

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

Georgina Long et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Immune control by amino acid catabolism during tumorigenesis and therapy

Henrique Lemos et al.

NATURE REVIEWS CANCER (2019)

添加到收藏夹

Review Oncology

The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy

Lieve Brochez et al.

EUROPEAN JOURNAL OF CANCER (2017)

添加到收藏夹

Article Chemistry, Medicinal

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (ID01) Inhibitor for Immunooncology

Eddy W. Yue et al.

ACS MEDICINAL CHEMISTRY LETTERS (2017)

添加到收藏夹

Article Chemistry, Medicinal

Phenyl Benzenesulfonylhydrazides Exhibit Selective Indoleamine 2,3-Dioxygenase Inhibition with Potent in Vivo Pharmacodynamic Activity and Antitumor Efficacy

Shu-Yu Lin et al.

JOURNAL OF MEDICINAL CHEMISTRY (2016)

添加到收藏夹

Article Chemistry, Medicinal

Identification of Substituted Naphthotriazolediones as Novel Tryptophan 2,3-Dioxygenase (TDO) Inhibitors through Structure-Based Virtual Screening

Jian-Sung Wu et al.

JOURNAL OF MEDICINAL CHEMISTRY (2015)

添加到收藏夹

Article Chemistry, Medicinal

Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors

Ming-Fu Cheng et al.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Ipilimumab in Advanced Melanoma

Jedd D. Wolchok et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

添加到收藏夹

Article Medicine, General & Internal

Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Article Medicine, General & Internal

Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer

Suzanne L. Topalian et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Review Oncology

Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives

Jessica Godin-Ethier et al.

CLINICAL CANCER RESEARCH (2011)

添加到收藏夹

Review Immunology

Control of immune response by amino acid metabolism

Ursula Grohmann et al.

IMMUNOLOGICAL REVIEWS (2010)

添加到收藏夹

Article Medicine, General & Internal

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

添加到收藏夹

Review Hematology

The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology

Antonio Curti et al.

BLOOD (2009)

添加到收藏夹

Review Oncology

Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?

Stefan Loeb et al.

NATURE REVIEWS CANCER (2009)

添加到收藏夹

Article Immunology

The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation

Wei Chen et al.

JOURNAL OF IMMUNOLOGY (2008)

添加到收藏夹

Review Oncology

Immunosuppressive networks in the tumour environment and their therapeutic relevance

WP Zou

NATURE REVIEWS CANCER (2005)

添加到收藏夹

Article Biochemistry & Molecular Biology

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

C Uyttenhove et al.

NATURE MEDICINE (2003)

添加到收藏夹

Article Biochemistry & Molecular Biology

Synergistic transcriptional activation of indoleamine dioxygenase by IFN-γ and tumor necrosis factor-α

CM Robinson et al.

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2003)

添加到收藏夹

Article Immunology

Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division

GK Lee et al.

IMMUNOLOGY (2002)

添加到收藏夹

Article Immunology

Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase

G Frumento et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2002)

添加到收藏夹

Article Biochemistry & Molecular Biology

Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor α in interferon-treated epithelial cells

TA Babcock et al.

CYTOKINE (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.